pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
NOVO · news · pharmadog
← back to NOVO
News mentioning NOVO
475
stories
12h
LENZ cuts 75% of staff as third quarter earnings disappoint
biospace
12h
STAT+: HHS green lights six peptides, despite concerns from FDA scientists
stat
13h
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
biospace
13h
STAT+: Pharmalittle: We’re reading about a new policy for compounding peptides, a PBM disclosure rule, and more
stat
15h
Flagship blends three biotech startups to form Etcelera
biopharma dive
17h
STAT+: Biopharma industry at odds over impact of Treasury’s new China rule
stat
22h
Biopharma cuts at manufacturing plants expected to affect 4,000+
biospace
22h
8 companies hiring in New York
biospace
1d
STAT+: Lawmaker wants government watchdog to probe TrumpRx over claims about drug savings
stat
1d
Flagship brings 3 biotech platforms together to launch AI drug discovery player Etcelera
fiercebiotech
1d
STAT+: HHS moves to allow compounding of some unapproved peptides
stat
1d
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
biopharma dive
1d
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
stat
1d
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
stat
1d
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
biospace
1d
Lilly's triple-G drug retatrutide outshines Novo's Ozempic in diabetes
endpoints
1d
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
stat
1d
Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
fiercebiotech
1d
5 new drug launches that defied industry expectations
biospace
1d
Behind the scenes of 3 Big Pharma layoffs
biospace
2d
STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts
stat
2d
Lilly's ads can continue after Novo challenge, judge rules
endpoints
2d
Court rejects Novo bid to block Lilly obesity drug ads
biopharma dive
2d
STAT+: Nonprofit resurrects shelved gene therapy after startup shuts down
stat
2d
STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more
stat
3d
Recon: FDA approves treatments for prostate cancer, Crohn’s disease; US judge refuses to halt Lilly weight-loss drug ads
raps
3d
Experts offer insights on de novo requests, MDUFA VI changes
raps
3d
Corxel, an obesity drugmaker, to go public via SPAC deal
biopharma dive
3d
Anthropic lays out drug R&D ambitions, risks in mammoth IPO filing
fiercebiotech
7d
GLP-1 compounder issues recall for copycat Zepbound
biopharma dive
← prev
page 1 of 16
next →
